ATE167859T1 - Antiproliferative 4h-naphtho(1,2-b)pyranderivate - Google Patents

Antiproliferative 4h-naphtho(1,2-b)pyranderivate

Info

Publication number
ATE167859T1
ATE167859T1 AT92309169T AT92309169T ATE167859T1 AT E167859 T1 ATE167859 T1 AT E167859T1 AT 92309169 T AT92309169 T AT 92309169T AT 92309169 T AT92309169 T AT 92309169T AT E167859 T1 ATE167859 T1 AT E167859T1
Authority
AT
Austria
Prior art keywords
alkyl
phenyl
optionally substituted
hydroxy
carboxy
Prior art date
Application number
AT92309169T
Other languages
English (en)
Inventor
Colin Peter Dell
Colin William Smith
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919121358A external-priority patent/GB9121358D0/en
Priority claimed from GB929213058A external-priority patent/GB9213058D0/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE167859T1 publication Critical patent/ATE167859T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • C07D311/80Dibenzopyrans; Hydrogenated dibenzopyrans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • C07D311/92Naphthopyrans; Hydrogenated naphthopyrans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT92309169T 1991-10-09 1992-10-08 Antiproliferative 4h-naphtho(1,2-b)pyranderivate ATE167859T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919121358A GB9121358D0 (en) 1991-10-09 1991-10-09 Pharmaceutical compounds
GB929213058A GB9213058D0 (en) 1992-06-19 1992-06-19 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
ATE167859T1 true ATE167859T1 (de) 1998-07-15

Family

ID=26299655

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92309169T ATE167859T1 (de) 1991-10-09 1992-10-08 Antiproliferative 4h-naphtho(1,2-b)pyranderivate

Country Status (22)

Country Link
US (1) US5284868A (de)
EP (1) EP0537949B1 (de)
JP (1) JPH05194477A (de)
KR (1) KR100228841B1 (de)
CN (1) CN1034938C (de)
AT (1) ATE167859T1 (de)
AU (1) AU658003B2 (de)
CA (1) CA2079428A1 (de)
CZ (1) CZ281688B6 (de)
DE (1) DE69226060T2 (de)
DK (1) DK0537949T3 (de)
ES (1) ES2117035T3 (de)
FI (1) FI924551A (de)
HU (1) HU218916B (de)
IL (1) IL103356A (de)
MX (1) MX9205714A (de)
MY (1) MY111368A (de)
NO (1) NO301587B1 (de)
NZ (1) NZ244627A (de)
PH (1) PH30659A (de)
RU (1) RU2071472C1 (de)
TW (1) TW221292B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9203497D0 (en) * 1992-02-19 1992-04-08 Lilly Industries Ltd Pharmaceutical compounds
EP1004584A3 (de) * 1992-11-18 2000-07-05 Eli Lilly And Company Limited Pyranochinolin Derivate als Inhibitoren der Zellproliferation
GB9306062D0 (en) * 1993-03-24 1993-05-12 Lilly Industries Ltd Pharmaceutical compounds
EP0619314A1 (de) * 1993-04-09 1994-10-12 Eli Lilly And Company 4-Phenyl-4H-Naphtho 2,1-b pyran Derivate und ihre Verwendung als Arzneimittel
WO1995008289A2 (en) * 1993-09-16 1995-03-30 Scimed Life Systems, Inc. Percutaneous repair of cardiovascular anomalies and repair compositions
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease
US5665591A (en) * 1994-12-06 1997-09-09 Trustees Of Boston University Regulation of smooth muscle cell proliferation
DK0914102T3 (da) 1996-05-24 2006-01-09 Angiotech Pharm Inc Præparater og fremgangsmåder til behandling eller forebyggelse af syddomme i legemskanaler
IL119069A0 (en) 1996-08-14 1996-11-14 Mor Research Applic Ltd Pharmaceutical composition comprising tyrphostins
PT1230232E (pt) 1999-11-05 2004-07-30 Cytovia Inc 4h-cromeno substituido e seus analogos como activadores de caspases e indutores de apoptose e sua utilizacao
US6858607B1 (en) 2001-05-16 2005-02-22 Cytovia, Inc. 7,8-fused 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof
EP1392283A4 (de) * 2001-05-16 2004-10-20 Cytovia Inc Substituierte cumarine und chinoline als caspase-aktivatoren
EP1392683B1 (de) * 2001-05-16 2009-12-02 Cytovia, Inc. Substituierte 4h-chromene und analoga als aktivatoren von caspasen und induktoren von apoptose, und deren verwendung als antikrebsmittel
AU2003241482A1 (en) * 2002-05-16 2003-12-02 Cytovia, Inc. Substituted 4h-chromenes, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof
EP1509515A4 (de) * 2002-05-16 2006-07-05 Cytovia Inc SUBSTITUIERTE 4-ARYL-4H-PYRROLO ç2,3-H]CHROMENE UND ANALOGA ALS AKTIVATOREN VON CASPASEN UND APOPTOSEINDUKTOREN UND DEREN VERWENDUNG
US20040127519A1 (en) * 2002-12-12 2004-07-01 Pharmacia Corporation Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors
US20040127511A1 (en) * 2002-12-12 2004-07-01 Pharmacia Corporation Tricyclic aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2
WO2006026832A1 (en) * 2004-09-09 2006-03-16 Howard Florey Institute Of Experimental Physiology And Medicine Enzyme inhibitors and uses thereof
US20080146655A1 (en) * 2005-02-16 2008-06-19 Md Bioalpha Co., Ltd. Pharmaceutical Composition for the Treatment or Prevention of Diseases Involving Obesity, Diabetes, Metabolic Syndrome, Neuro-Degenerative Diseases and Mitochondria Dyfunction Diseases
US20080183282A1 (en) * 2006-03-09 2008-07-31 Saul Yedgar Use of lipid conjugates for the coating of stents and catheters
US8263775B2 (en) 2007-11-19 2012-09-11 Howard Florey Institute Insulin-regulated aminopeptidase (IRAP) inhibitors and uses thereof
EA015364B1 (ru) * 2009-03-18 2011-06-30 Учреждение Российской Академии Наук Институт Элементоорганических Соединений Им. А.Н. Несмеянова Ран (Инэос Ран) 6,6'-диизопропил-8,8'-диметил-2,2'-динитро-3,3'-бис(трифторметил)- 3н,3'н-[9,9']ди[бензо(f)хроменил]-5,10,5',10'-тетраол, обладающий противоопухолевой и противогрибковой активностью, и способ его получения
CN107235954A (zh) 2010-11-12 2017-10-10 德国癌症研究中心 作为Wnt通路拮抗剂的色烯衍生物及其类似物
US20140275174A1 (en) 2011-11-10 2014-09-18 Memorial Sloan-Kettering Cancer Center TREATMENT OF OVARIAN CANCER WITH 2-AMINO-4H-NAPHTHO[1,2-b]PYRAN-3-CARBONITRILES

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU724509A1 (ru) * 1978-09-21 1980-03-30 Пермский государственный фармацевтический институт Способ получени 2-ароил-3н- нафто 2,1-в пиранонов-3
US5232942A (en) * 1988-04-14 1993-08-03 Yamanouchi Pharmaceutical Co., Ltd. Q-2819 substance and the use thereof

Also Published As

Publication number Publication date
FI924551A0 (fi) 1992-10-08
US5284868A (en) 1994-02-08
JPH05194477A (ja) 1993-08-03
ES2117035T3 (es) 1998-08-01
HU9203183D0 (en) 1992-12-28
PH30659A (en) 1997-09-16
MX9205714A (es) 1993-04-01
CZ281688B6 (cs) 1996-12-11
HUT62281A (en) 1993-04-28
CN1073437A (zh) 1993-06-23
KR100228841B1 (ko) 1999-11-01
NO923910D0 (no) 1992-10-08
DK0537949T3 (da) 1999-02-15
CZ303592A3 (en) 1993-12-15
AU2621692A (en) 1993-04-22
CN1034938C (zh) 1997-05-21
FI924551A (fi) 1993-04-10
AU658003B2 (en) 1995-03-30
NO923910L (no) 1993-04-13
MY111368A (en) 1999-12-31
HU218916B (hu) 2000-12-28
CA2079428A1 (en) 1993-04-10
NZ244627A (en) 1994-12-22
IL103356A (en) 1998-02-22
DE69226060D1 (de) 1998-08-06
NO301587B1 (no) 1997-11-17
EP0537949A1 (de) 1993-04-21
TW221292B (de) 1994-02-21
IL103356A0 (en) 1993-03-15
RU2071472C1 (ru) 1997-01-10
KR930007931A (ko) 1993-05-20
DE69226060T2 (de) 1998-11-19
EP0537949B1 (de) 1998-07-01

Similar Documents

Publication Publication Date Title
ATE167859T1 (de) Antiproliferative 4h-naphtho(1,2-b)pyranderivate
CO5150224A1 (es) Compuestos de triazol y su utilizacion
RS50484B (sr) Nova spiro jedinjenja
NO983099L (no) Nye retrovirale proteasehemmere
FI913782A (fi) Isoxazolderivat.
DK0641325T3 (da) Inhibitorer af retroviral protease
DK0444659T3 (da) Farmaceutisk opløsning indeholdende derivater af FK 506
DE69330639D1 (de) Methotrexat-derivate
FI942094A (fi) Kollagenaasin inhibiittori
ES2130258T3 (es) Compuesto amino terciario sustituido o sal de este compuesto.
RS51296B (sr) Novi cikloheksil sulfoni
MY109777A (en) Pharmaceutical compounds therewith
FI911138A0 (fi) Ny substituerad aminfoerening och foerfarande foer dess framstaellning.
DK0639173T3 (da) Visse 2- (2'-methyl-3', 4'-trisubstitueret benzoyl) -1,3-cyklohexandioner
DK0417746T3 (da) N-Azabicyclo(3.3.0)octanamider af aromatiske syrer
DE69113893D1 (de) 6,7-Disubstituierte 2-Aminotetraline als Immunomodulatoren und pharmazeutische Zusammensetzungen davon.
ATE145395T1 (de) 5-amino-2-phenoxysulfonanilid-derivate
TH17774A (th) อนุพันธ์ 1,3-ออกซาซิน-4-โอนชนิดใหม่ สารฆ่าวัชพืชที่มีอนุพันธ์เหล่านี้และสารมัธยันตร์สำหรับการเตรียอนุพันธ์เหล่านี้
MX9204939A (es) Inhibidores 5-bis-aminometilen-1,3-dioxan-4,6-diona n,n',n'-trisubstituidas, de la acil coenzima a: colesterol-aciltransferasa.
ATE154243T1 (de) Hemmstoff der blutgefässhypertrophie
TH17774EX (th) อนุพันธ์ 1,3-ออกซาซิน-4-โอนชนิดใหม่ สารฆ่าวัชพืชที่มีอนุพันธ์เหล่านี้และสารมัธยันตร์สำหรับการเตรียอนุพันธ์เหล่านี้

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee